News
GSK falls
Digest more
ViiV Healthcare has announced steps to widen access to a sought-after HIV medicine in low- and middle-income countries, ...
New data from the VOLITION study reveal that 89% of treatment-naïve individuals with HIV chose to switch to long-acting cabotegravir and rilpivirine after achieving viral suppression with oral DTG/3TC ...
HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...
ViiV Healthcare, the HIV-focused joint venture majority owned by GSK, said on Monday it has expanded its licensing deal with the Medicines Patent Pool to allow generic production of its long-acting ...
GSK expands Medicines Patent Pool deal to allow generic production of cabotegravir for HIV treatment
GSK has expanded its voluntary licensing agreement with the United Nations-backed Medicines Patent Pool (MPP) for cabotegravir, allowing it to be produced by three generic drugmakers and supplied to ...
President Trump said he was likely to impose tariffs on pharmaceuticals as soon as the end of the month, starting with a "low ...
GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...
GlobalData on MSN3d
WHO endorses Gilead’s Yeztugo for HIV preventionThe WHO’s Director-General described the policy guidelines for Gilead’s twice-yearly drug as the “next best thing” in the ...
No investor will be happy with their GSK shares as the FTSE 100 pharmaceutical giant has had a dismal decade. Will the next ...
Hyderabad-based drugmaker Aurobindo Pharma will produce and supply Cabotegravir, a long-acting injectable HIV treatment, ...
UK-based ViiV Healthcare, the HIV specialist company majority owned by GSK, with Pfizer and Shionogi as shareholders, has announced data from the Phase IIIb VOLITION study.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback